<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Antidepressants: tricyclic; Tricyclic antidepressants see Antidepressants, tricyclic; Antidepressants: choice; Amitriptyline: depression; Clomipramine; Dosulepin; Doxepin; Mianserin; Trazodone; Trimipramine; Imipramine: depression; Lofepramine; Nortriptyline: depression" /><meta name="IX" content="Antidepressants: tricyclic; Antidepressants: choice; Amitriptyline: depression; Clomipramine; Dosulepin; Doxepin; Mianserin; Trazodone; Trimipramine; Imipramine: depression; Lofepramine; Nortriptyline: depression" /><meta name="IXN" content="Tricyclic antidepressants see Antidepressants, tricyclic" /><title>4.3.1 Tricyclic and related antidepressant drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="3295.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="3295.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=3295.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2055.htm">4 Central nervous system</a> &gt; <a href="3294.htm">4.3 Antidepressant drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="3294.htm" title="Previous: 4.3 Antidepressant drugs">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="3296.htm" title="Next: Tricyclic antidepressants">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_3295">4.3.1 Tricyclic and related antidepressant drugs</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i252.htm" title="Go to appendix 1">Antidepressants, Tricyclic (related)</a>, <a rel="appendix" href="41001i241.htm" title="Go to appendix 1">Antidepressants, Tricyclic</a>).</div><div><p>This section covers tricyclic
antidepressants and also 1-, 2-, and 4-ring structured drugs with
broadly similar properties.</p><p>Some tricyclic antidepressants are used in the management of <i>panic</i> and other <i>anxiety disorders</i> (<a title="section: Antidepressant drugs" href="3294.htm#_3294">section 4.3</a>). For reference to the role of
some tricyclic antidepressants in some forms of <i>neuralgia</i>, see <a title=" Neuropathic pain" href="3548.htm#_3548">section 4.7.3</a>, and in <i>nocturnal enuresis</i> in
children, see <a title="BNF:monograph-family: Nocturnal enuresis" href="4638.htm#_4638">section 7.4.2</a>.</p><div id="_202779"><div class="cAZ"><h2>Cautions</h2> <p class="cAX">Tricyclic and related antidepressant
drugs should be used with caution in patients with cardiovascular
disease (see also Contra-indications, below); because
of the risk of arrhythmias, patients with concomitant conditions such
as hyperthyroidism and phaeochromocytoma should be treated with care. Care is also needed in patients with epilepsy and diabetes.</p><p>Tricyclic antidepressant drugs have antimuscarinic activity,
and therefore caution is needed in patients with prostatic
hypertrophy, chronic constipation, increased intra-ocular pressure, urinary retention, or those with a susceptibility
to angle-closure glaucoma. Tricyclic and related antidepressant
drugs should be used with caution in patients with a
significant risk of suicide, or a history
of psychosis or bipolar disorder, because antidepressant therapy may aggravate
these conditions; treatment should be stopped if the
patient enters a manic phase.</p><p>Elderly patients are particularly susceptible to many of the
side-effects of tricyclic antidepressants; low initial doses should
be used, with close monitoring, particularly for psychiatric and cardiac
side-effects.</p></div></div><div id="_3295.1"><div class="cAZ"><h2>Overdosage</h2> <p class="cAX">Limited quantities of
tricyclic antidepressants should be prescribed at any one time because
their cardiovascular and epileptogenic effects are dangerous in overdosage. In particular, overdosage with dosulepin and amitriptyline is associated
with a relatively high rate of fatality. Lofepramine is associated
with the lowest risk of fatality in overdosage, in comparison with
other tricyclic antidepressant drugs. For advice on <b>overdosage</b> see <a title="monograph-family: Antidepressants" href="29539.htm#_29539">Emergency Treatment of Poisoning</a>.</p></div></div><div id="_203820"><div class="cAZ"><h2>Withdrawal</h2> <p class="cAX">Withdrawal symptoms include influenza-like
symptoms (chills, myalgia, sweating, headache, nausea), insomnia,
vivid dreams, and may occasionally include movement disorders and
mania. If possible tricyclic and related antidepressants
should be withdrawn slowly (see also <a title=" Antidepressant drugs" href="3294.htm#_3294">section 4.3</a>).</p></div></div><div class="cAZ"><h2>Interactions</h2> <p class="cAX">A tricyclic or related antidepressant
(or an SSRI or related antidepressant) should not be started until
2 weeks after stopping an MAOI (3 weeks if starting clomipramine or
imipramine). Conversely, an MAOI should not be started until at least
7–14 days after a tricyclic or related antidepressant (3 weeks in
the case of clomipramine or imipramine) has been stopped. For guidance
relating to the reversible monoamine oxidase inhibitor, <span>moclobemide</span>, see <a title="target-block: Moclobemide interaction guidance" href="3348.htm#_120536">section 4.3.2</a>. For other tricyclic antidepressant <b>interactions</b>, see Appendix 1 (antidepressants, tricyclic and antidepressants,
tricyclic (related)).</p></div><div id="_202781"><div class="cAZ"><h2>Driving</h2> <p class="cAX">Drowsiness may affect the
performance of skilled tasks (e.g. driving); effects of alcohol enhanced.</p></div></div><div id="_202782"><div class="cAZ"><h2>Contra-indications</h2> <p class="cAX">Tricyclic and related antidepressants
are contra-indicated in the immediate recovery period after
myocardial infarction, in arrhythmias (particularly heart block), and in the manic phase of bipolar disorder. Avoid treatment
with tricyclic antidepressant drugs in acute porphyria (<a title="BNF:sub-section: Acute porphyrias" href="5181.htm#_5181">section 9.8.2</a>).</p></div></div><div id="_203955"><div class="cAZ"><h2>Hepatic impairment</h2> <p class="cAX">Tricyclic antidepressants are
preferable to MAOIs in hepatic impairment but sedative effects are
increased. They should be avoided in severe liver disease.</p></div></div><div id="_203956"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">The amount of tricyclic antidepressants
(including related drugs such as mianserin and trazodone) secreted
into breast milk is too small to be harmful (but see <a title="BNF:monograph: DOXEPIN" href="129885.htm#_129885">Doxepin</a>).</p></div></div><div id="_202662"><div class="cAZ"><h2>Side-effects</h2> <p class="cAX">Arrhythmias and heart block occasionally
follow the use of tricyclic antidepressants, particularly amitriptyline,
and may be a factor in the sudden death of patients with cardiac disease;
other cardiovascular side-effects include postural hypotension, tachycardia,
and ECG changes. The tricyclic-related antidepressant drugs may be
associated with a lower risk of cardiotoxicity in overdosage.</p><p>Central nervous system side-effects are common, particularly
in the elderly, and include anxiety, dizziness, agitation, confusion,
sleep disturbances, irritability, and paraesthesia; drowsiness is
associated with some of the tricyclic antidepressants (see under Choice,
below). Convulsions, hallucinations, delusions, mania, and hypomania
may occur (see also under Cautions, above), and, <i>rarely</i>, extrapyramidal symptoms including tremor and dysarthria.</p><p>Antimuscarinic side-effects include dry mouth, blurred vision
(<i>very rarely</i> precipitation of angle-closure glaucoma),
constipation (<i>rarely</i> leading to paralytic ileus,
particularly in the elderly), and urinary retention. Tricyclic-related
antidepressant drugs have a lower incidence of antimuscarinic side-effects
than older tricyclics.</p><p>Endocrine effects include breast enlargement, galactorrhoea,
and gynaecomastia. Sexual dysfunction may occur. Changes in blood
sugar, increased appetite, and weight gain can accompany treatment
with tricyclic antidepressant drugs, but anorexia and weight loss
are also seen. Hepatic and haematological reactions may occur and
have been particularly associated with mianserin. Another side-effect
to which the elderly are particularly susceptible is hyponatraemia
(see Hyponatraemia and Antidepressant Therapy, <a title=" Antidepressant drugs" href="3294.htm#_3294">section 4.3</a>). Other class side-effects
include nausea, vomiting, taste disturbance, tinnitus, rash, urticaria,
pruritus, photosensitivity, alopecia, and sweating.</p><p>The patient should be encouraged to persist with treatment as
some tolerance to these side-effects seems to develop. They are reduced
if low doses are given initially and then gradually increased, but
this must be balanced against the need to obtain a full therapeutic
effect as soon as possible. </p><p>Neuroleptic malignant syndrome (<a title=" Antipsychotic drugs" href="3209.htm#_3209">section 4.2.1</a>) may, very rarely, occur in the course of antidepressant
drug treatment.</p><p>Suicidal behaviour has been linked with antidepressants (see <a title="target-block: antidepressants and suicide" href="3294.htm#_3294.1">Suicidal Behaviour and Antidepressant
Therapy</a>).</p></div></div><div class="cAZ"><h2>Dosage</h2> <p class="cAX">About 10 to 20% of patients fail to respond
to tricyclic and related antidepressant drugs and inadequate dosage
may account for some of these failures. It is important to use doses
that are sufficiently high for effective treatment but not so high
as to cause toxic effects. Low doses should be used for initial treatment
in the <b>elderly</b> (see under Side-effects, below).</p><p>In most patients the long half-life of tricyclic antidepressant
drugs allows <b>once-daily</b> administration, usually at
night; the use of modified-release preparations is therefore unnecessary.</p></div><div class="cAZ"><h2>Choice</h2> <p class="cAX">Tricyclic and related antidepressants block the
re-uptake of both serotonin and noradrenaline, although to different
extents. For example, clomipramine is more selective for serotonergic
transmission, and imipramine is more selective for noradrenergic transmission.
Tricyclic and related antidepressant drugs can be roughly divided
into those with additional sedative properties and those that are
less sedating. Agitated and anxious patients tend to respond best
to the sedative compounds, whereas withdrawn and apathetic patients
will often obtain most benefit from the less sedating ones. Those
with <b>sedative</b> properties include amitriptyline, clomipramine, dosulepin, doxepin, mianserin, trazodone,
and <span>trimipramine</span>. Those with <b>less sedative</b> properties include imipramine, <span>lofepramine</span>,
and <span>nortriptyline</span>.</p><p>Tricyclic and related antidepressants also have varying degrees
of antimuscarinic side-effects and cardiotoxicity in overdosage, which
may be important in individual patients. <b>Lofepramine</b> has a lower incidence of side-effects and is less dangerous in overdosage
but is infrequently associated with hepatic toxicity. <b>Imipramine</b> is also well established, but has more marked antimuscarinic side-effects
than other tricyclic and related antidepressants. <b>Amitriptyline</b> and <b>dosulepin</b> are effective but they are particularly
dangerous in overdosage (see Overdosage, above) and are not recommended
for the treatment of depression; dosulepin should only be prescribed
by specialists.</p></div><div class="cAZ"><h2>Children and adolescents</h2> <p class="cAX">Studies have shown that
tricyclic antidepressants are not effective for treating depression
in children; see also <a title="target-block: CSM advice depression in children" href="3351.htm#_3351.3">Depressive Illness in Children
and Adolescents</a>.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_3296"><a href="3296.htm" title="Tricyclic antidepressants">Tricyclic antidepressants</a></li><li id="_3314"><a href="3314.htm" title="Tricyclic-related antidepressants">Tricyclic-related antidepressants</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="3294.htm">Previous: 4.3 Antidepressant drugs</a> | <a class="top" href="3295.htm#">Top</a> | <a accesskey="]" href="3296.htm">Next: Tricyclic antidepressants</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>